Wolfe Co-Chairs MG Panel; Treatment Options Expanded

Published December 15, 2020

story based on news release by ellen goldbaum

Gil I. Wolfe, MD, UB Distinguished Professor and the Irvin and Rosemary Smith Chair of neurology, served as co-chair for a panel composed of 16 international experts on myasthenia gravis (MG) who revised and expanded recommendations for managing the disease. 


Updates Guidelines Developed in 2016

Gil I. Wolfe, MD

The panel’s paper was published in the journal Neurology on Nov. 3.

Wolfe co-chaired the same panel in 2016, when the guidelines were originally developed.

The new guidance for clinicians is based on the latest evidence in the literature. This updated formal consensus guidance provides recommendations to clinicians caring for MG patients worldwide.

“Some wealthy countries have established their own guidelines, but most of the world cannot do that,” says Wolfe, the president of UBMD Neurology. “The international panel, using the UCLA/RAND Appropriateness Methodology to achieve a formal consensus, hopes to fill that void, providing a treatment/management framework for health care providers, industry, insurers and the patient community.”

Key Revision Encourages Thymectomy

MG is a rare autoimmune disease affecting neuromuscular function. As many as 60,000 Americans have been diagnosed with MG, and its incidence is increasing as a result of improved diagnostic techniques and an aging population. Symptoms of MG include droopy eyelids; blurred or double vision; difficulty speaking, swallowing and breathing; and muscle weakness.

One of the main revisions to the recommendations encourages thymectomy (surgical removal of the thymus gland) in the largest subpopulation of MG patients. This change is based on a clinical trial for which Wolfe was the principal investigator. Results of that trial were published in the New England Journal of Medicine in 2016 and in The Lancet Neurology in 2019.

A new recommendation was also developed for the use of eculizumab, a complement inhibitor that is the first Food and Drug Administration-approved immunotherapy for MG. 

The panel also revised recommendations for the use of rituximab and methotrexate, as well as for early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.

In addition, there are some warnings in the recommendations pertaining to worsening MG clinical status in regard to certain therapies that have been touted for use in COVID-19, Wolfe says.